Login / Signup

Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.

Mahima KapoorMary M ReillyHadi ManjiMichael P Lunnnull Aisling Snull Carr
Published in: The International journal of neuroscience (2020)
These six cases demonstrate the safety and effectiveness of a treatment approach that includes individualised but evidence-based clinical assessment and, when necessary, high-doses of IVIg to restore patients' strength and ability to participate in activities of daily activities. Careful patient selection is important.
Keyphrases
  • high dose
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • randomized controlled trial
  • chronic kidney disease
  • systematic review
  • prognostic factors
  • low dose
  • physical activity
  • combination therapy